{"id":"W2326027494","doi":"10.1097/00054725-200912002-00033","title":"Emerging Safety Profile of Vedolizumab: A novel, selective Integrin Inhibitor for the treatment of IBD","year":2009,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"","keywords":"Vedolizumab; Addressin; Medicine; Ulcerative colitis; Monoclonal antibody; Progressive multifocal leukoencephalopathy; Integrin; Immunology; Monoclonal; Crohn's disease; Cell adhesion molecule; Antibody; Internal medicine; Disease; Receptor; Virus","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003892132,0.0003528812,0.001294252,0.0004726126,0.0001878866,0.0008470074,0.0005241793,0.0007725797,0.001441318],"category_scores_gemma":[0.003088548,0.0001295815,0.0006680122,0.0004746416,0.0002894668,0.0005325371,0.0002181801,0.0009176645,0.0003450253],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004996736,"about_ca_system_score_gemma":0.0003670923,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002460381,"about_ca_topic_score_gemma":0.0004331954,"domain_scores_codex":[0.9987839,0.0004291799,0.0001626997,0.0001310321,0.0004315032,0.00006174631],"domain_scores_gemma":[0.9966409,0.001425405,0.0008903028,0.0001270575,0.0007124216,0.0002039314],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.02946745,0.001364308,0.07202739,0.00350807,0.001377602,0.001579803,0.0003006614,0.002742856,0.2079817,0.0009621852,0.004099281,0.6745887],"study_design_scores_gemma":[0.01377618,0.2430626,0.4879796,0.00119009,0.00474193,0.02247938,0.0003849714,0.009519452,0.1078397,0.002410569,0.1064617,0.0001539308],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8308522,0.1515185,0.006844544,0.002845503,0.0001965954,0.0003329718,0.001802815,0.0001638336,0.005443153],"genre_scores_gemma":[0.9695145,0.02232828,0.002263015,0.001547896,0.0006842571,0.0001265262,0.002562185,0.00003164032,0.0009418693],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003892132,"threshold_uncertainty_score":0.02058387,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007955060842697566,"score_gpt":0.2494157312788143,"score_spread":0.2414606704361167,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}